{"id":"W2950944873","doi":"10.1097/01.hs9.0000563756.72895.a3","title":"PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW‐UP OF THE PHASE 2, RANDOMIZED ELOQUENT‐3 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Internal medicine; Dexamethasone; Oncology; Multiple myeloma; Combination therapy; Ixazomib; Refractory (planetary science); Progression-free survival; Bortezomib; Overall survival; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003160996,0.001303397,0.001897405,0.0004256822,0.0003267503,0.001540531,0.0008877787,0.001162513,0.003972691],"category_scores_gemma":[0.001736637,0.0004122273,0.0026133,0.0005403882,0.0008290776,0.001294911,0.0004522133,0.003412362,0.00108475],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001429613,"about_ca_system_score_gemma":0.001224422,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009082383,"about_ca_topic_score_gemma":0.002560784,"domain_scores_codex":[0.9991732,0.0004053692,0.0000419132,0.0001236659,0.0001129089,0.0001428273],"domain_scores_gemma":[0.9989892,0.0002334602,0.0002507698,0.00009872807,0.00008501992,0.0003428356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8318126,0.02089235,0.003713566,0.001174714,0.004105468,0.0001855282,0.0001933439,0.001857773,0.01093248,0.0004796419,0.006774798,0.1178777],"study_design_scores_gemma":[0.8352334,0.1393503,0.01514035,0.0001234032,0.002010387,0.0002819848,0.00007107649,0.001191047,0.001685241,0.0006097163,0.004254795,0.00004820112],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9782462,0.01065791,0.0008577224,0.001385933,0.0003160805,0.001818675,0.003293253,0.0001824101,0.003241913],"genre_scores_gemma":[0.9830326,0.004126627,0.001448998,0.002264607,0.0003275484,0.001343903,0.005307801,0.00005788282,0.002090005],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003972691,"threshold_uncertainty_score":0.01671714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02534817731838447,"score_gpt":0.3125158143310527,"score_spread":0.2871676370126683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}